1. Home
  2. XPEL vs ELVN Comparison

XPEL vs ELVN Comparison

Compare XPEL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XPEL
  • ELVN
  • Stock Information
  • Founded
  • XPEL 1999
  • ELVN 2016
  • Country
  • XPEL United States
  • ELVN United States
  • Employees
  • XPEL N/A
  • ELVN N/A
  • Industry
  • XPEL Industrial Specialties
  • ELVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • XPEL Industrials
  • ELVN Health Care
  • Exchange
  • XPEL Nasdaq
  • ELVN Nasdaq
  • Market Cap
  • XPEL 1.2B
  • ELVN 1.1B
  • IPO Year
  • XPEL N/A
  • ELVN 2020
  • Fundamental
  • Price
  • XPEL $40.20
  • ELVN $22.71
  • Analyst Decision
  • XPEL Buy
  • ELVN Strong Buy
  • Analyst Count
  • XPEL 2
  • ELVN 5
  • Target Price
  • XPEL $49.00
  • ELVN $37.80
  • AVG Volume (30 Days)
  • XPEL 121.9K
  • ELVN 187.5K
  • Earning Date
  • XPEL 02-20-2025
  • ELVN 11-13-2024
  • Dividend Yield
  • XPEL N/A
  • ELVN N/A
  • EPS Growth
  • XPEL N/A
  • ELVN N/A
  • EPS
  • XPEL 1.75
  • ELVN N/A
  • Revenue
  • XPEL $418,411,000.00
  • ELVN N/A
  • Revenue This Year
  • XPEL $8.08
  • ELVN N/A
  • Revenue Next Year
  • XPEL $13.97
  • ELVN N/A
  • P/E Ratio
  • XPEL $22.93
  • ELVN N/A
  • Revenue Growth
  • XPEL 13.32
  • ELVN N/A
  • 52 Week Low
  • XPEL $30.75
  • ELVN $10.90
  • 52 Week High
  • XPEL $60.49
  • ELVN $30.03
  • Technical
  • Relative Strength Index (RSI)
  • XPEL 34.03
  • ELVN 41.94
  • Support Level
  • XPEL $39.48
  • ELVN $21.43
  • Resistance Level
  • XPEL $44.50
  • ELVN $24.42
  • Average True Range (ATR)
  • XPEL 1.46
  • ELVN 1.63
  • MACD
  • XPEL -0.58
  • ELVN 0.02
  • Stochastic Oscillator
  • XPEL 9.96
  • ELVN 28.34

About XPEL XPEL Inc.

XPEL Inc is a provider of protective films and coatings, including automotive paint protection film, surface protection film, automotive and commercial/residential window films, and ceramic coatings. The company has a network of trained installers and proprietary DAP software, dedicated to exceeding customer expectations by providing quality products, customer service, technical support, and world-class training. The majority of revenue is derived from the United states.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Share on Social Networks: